Arecor Therapeutics plc (LON:AREC – Get Free Report) reached a new 52-week low on Tuesday . The company traded as low as GBX 130 ($1.62) and last traded at GBX 130.24 ($1.62), with a volume of 16323 shares changing hands. The stock had previously closed at GBX 132.50 ($1.65).
Arecor Therapeutics Price Performance
The business has a 50-day simple moving average of GBX 143.89 and a 200 day simple moving average of GBX 169.05. The firm has a market cap of £39.82 million, a P/E ratio of -419.35 and a beta of -0.22. The company has a debt-to-equity ratio of 1.26, a quick ratio of 6.24 and a current ratio of 2.52.
About Arecor Therapeutics
Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products.
Further Reading
- Five stocks we like better than Arecor Therapeutics
- Best Stocks Under $5.00
- Silicon Motion Proves That AI in Motion Stays in Motion
- How to Invest in Biotech Stocks
- Undervalued UnitedHealth Group Won’t Be For Long
- What is an Earnings Surprise?
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
